The objective of this prospectively randomized phase II trial ( Trial registration : EUCTR2004-004007-37-DE ) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone ( LET ) or letrozole and zoledronic acid ( LET + ZOL ) .